Patients' subjective experiences of antipsychotics: Clinical relevance

CNS Drugs

Volumn 16, Issue 7, 2002, Pages 457-471

  Hellewell, Jonathan S E ^a  

^a TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DROWSINESS; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERSALIVATION; HYPOKINESIA; ILLNESS BEHAVIOR; META ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; REVIEW; SAMPLE SIZE; SCHIZOPHRENIA; SELF REPORT; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; WELLBEING;

EID: 0036305380     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216070-00003     Document Type: Review

References (61)

1. Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: A multinational survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics
2. Clinical services research
3. Methodological standards for treatment outcome research in schizophrenia
4. Measurement of therapeutic response in schizophrenia: A critical survey
5. The well-being of chronic mental patients
6. The relationship of symptoms and level of functioning in schizophrenia to general well-being and the Quality of Life Scale
7. Intervention research in psychosis: Issues related to the assessment of quality of life
8. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia
9. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
10. Subjective response as a predictor of outcome in pharmacotherapy
11. Subjective effects of neuroleptics predict compliance
12. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life
13. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability
14. Subjective experiences of schizophrenic patients treated with antipsychotic medication
15. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
16. Health beliefs and compliance with antipsychotic medication
17. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
18. Medication compliance: The patient's perspective
19. Differences in health values among patients, family members and providers for outcomes in schizophrenia
20. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs
21. The positive and negative syndrome scale (PANSS) for schizophrenia
22. Akinesia: A poorly recognised drug-induced extrapyramidal behavioural disorder
23. Neuroleptic-induced anhedonia: Recent studies
24. Neuroleptic induced deficit syndrome: Old problem, new challenge
25. Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome
26. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity
27. Predicting medication noncompliance after hospital discharge among patients with schizophrenia
28. Measures of quality of life among persons with severe and persistent mental disorders
29. Quality of life of seriously mentally ill persons in Mississippi
30. Preliminary validation of conceptual model to assess quality of life in schizophrenia
31. Treatment with neuroleptics: The patient's perspective
32. Subjective experience of treatment, side-effects, mental state and quality of life in schizophrenic outpatients treated with depot neuroleptics
33. The UKU side effect rating scale
34. Subjective experience and mental side effects of antipsychotic treatment
35. The content and context of compliance
36. The many faces of akathisia
37. Suicide attempts associated with akathisia
38. Clinical management of clozapine patients in relation to efficacy and side-effects
39. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: Correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging
40. The new generation antipsychotics: Opportunities and challenges
41. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone or haloperidol
42. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol
43. Amisulpride versus risperidone in schizophrenia: Comparing clinical and functional outcome in a 6 month study
44. Investigation of the subjective well-being of psychotic patients under neuroleptic therapy
45. Clozapine: A survey of patient perceptions
46. Subjective experiences of clozapine treatment by patients with chronic schizophrenia
47. Patient satisfaction with, and acceptability of, atypical antipsychotics
48. Patient satisfaction and the acceptability of long-term treatment with quetiapine
49. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia
50. Subjective experience of patients on olanzapine in comparison to other antipsychotics
51. The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance
52. Clinical Global Impressions
53. Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia
54. Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia
55. Risperidona: Una alternativa real en pacientes tratados con neurolepticos depot
56. Influence of novel and conventional antipsychotic medication on subjective quality of life
57. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerabitity, side effect profile and impact on quality of life
58. A rating scale for drug-induced akathisia
59. The quality of life scale: An instrument for rating the schizophrenic deficit scale
60. The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients